Harrow (HROW) Change in Account Payables (2010 - 2018)

Harrow (HROW) posted quarterly Change in Account Payables of $64000.0 for Q3 2018, up 264.1% quarter-over-quarter from -$39000.0 in Q2 2018.

Harrow (HROW) Change in Account Payables (2010 - 2018) Analysis & Trends

Harrow's Change in Account Payables history runs 8 years deep, the most recent figure standing at $64000.0 for Q3 2018.

In Q3 2018, Change in Account Payables changed N/A year-over-year to $64000.0; the TTM figure through Sep 2018 stood at $90000.0 (up 195.74% YoY), while the FY2017 annual figure was -$62000.0, down 338.46% from the prior year.
Change in Account Payables for Q3 2018 stood at $64000.0, up from -$39000.0 in the prior quarter.
The five-year high for Change in Account Payables was $64000.0 in Q3 2018, with the low at -$83000.0 in Q1 2017.
The 5-year median for Change in Account Payables is $500.0 (2014), against an average of $428.57.
Peak annual rise in Change in Account Payables reached 4500.0% in 2015, while the deepest fall reached 2700.0% in 2015.
Harrow's Change in Account Payables stood at -$1000.0 in 2014, then jumped by 4500.0% to $44000.0 in 2015, then tumbled by 125.0% to -$11000.0 in 2016, then surged by 290.91% to $21000.0 in 2017, then soared by 204.76% to $64000.0 in 2018.
Business Quant data shows HROW's Change in Account Payables at $64000.0 in Q3 2018, -$39000.0 in Q2 2018, and $44000.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Account Payables (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	-
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	-53.00 Mn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	-143.74 Mn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	-
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	-21.20 Mn
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	-
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Harrow	1.53 Bn	1.45 Bn	50.36 Mn	-

Download Data